LATEST NEWS
  •  
    Advanced Track and Trace for Pharma could streamline both manufacturing and warehousing data collection and reporting
    The enterprise-level resource planning (ERP) and financial management tools of SAP AG are widely used in the life sciences industry, and life sciences in turn is a strategic industry focus of the Walldorf, Germany firm. And while SAP has had a solution set that can address the needs of pharma companies performing traceability or authentication processes in drug distribution, those software tools have been general ones applicable to many industries--implying significant configuration complexity to handle the specific needs of pharma. That will now change with the imminent release of SAP Advanced Track and Trace for Pharma (ATT for Pharma)--a strategic area
  •  
    Annual survey ranks Good Neighbor Pharmacy as No. 1
    The consumer-sentiment surveyor J.D. Power and Associates (Westlake Village, CA) finds Good Neighbor Pharmacy, the franchise organization run by AmerisourceBergen, on top among chain and independent pharmacies nationally. By measuring five factors (prescription ordering; store; cost competitiveness; non-pharmacist staff; and pharmacist) and ranking on a 1000-point scale, J.D. Power puts Good Neighbor at 876, just nosing out Health Mart (McKesson's similar franchising operation), at 875, and the Medicine Shoppe (a franchising organization owned by Cardinal Health) at 861. The average for all chains was 842, while supermarket pharmacies came in at 851
  •  
    Projected to grow 9% (CAGR) through 2020
    Laboratory rats are such a common element of drug research that the term is also used for those who work in the field. And while there are many, many drugs that showed promise during this form of animal testing but later failed (and despite the efforts of animal activists to restrict the activity), lab rats are still an essential tool for researchers. Marketsandmarkets, a Pune, India, market research firm, has just announced a study putting the overall business at $358 million in 2014, rising to $602 million by 2020. And, just as, say, chromatographs come in varieties like liquid, gas, high-pressure and such, lab rats come in a growing variety
  •  
    50% expansion adds to facility's pharma capacity; emphasis on cold chain services
    Kuehne + Nagel, one of the largest global logistics companies, has built up its KN PharmaChain brand of healthcare logistics solutions in recent years, with its Contract Logistics division sharing in the growth of this overall category. Now, it is adding roughly 50% more capacity to its Memphis, TN facility, which already has over 200,000 sq. ft. of warehouse capacity, mostly dedicated to life sciences. A 10-year contract with an unspecified client has enabled the company to add 117,000 sq. ft, including 36,800 for 2-8C service, 24,500 for -25C cryogenic service, and 43,000 for controlled-ambient conditions. An additional 20,000 sq. ft. is available for packaging
  •  
    PhRMA rapidly responds: 'a chilling signal to the marketplace that risk-taking will no longer be rewarded'
    A commentary published in the latest Mayo Clinic Proceedings, signed by dozens of (mostly) academically affiliated oncologists, calls for a new effort to corral the prices of cancer drugs entering the market. The in-press article, "In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs" calls for patients and the public to sign a petition in hopes that "this quantified support can then be used by advocates, lobbyists and others to ... encourage our elected representatives to more effectively advocate for ... patients." The physicians cite data indicating that the average price of new cancer drugs has increased 5- to 10-fold over 15 years, and the cost of drugs for each
  •  
    Sofrigam promotes its Igloo kit for pharmacy-to-home; Sonoco, a new reusable container
    Years ago (and, worrisomely, in some cases still today) pharma cold chain packaging amounted to beer coolers with some ice thrown in, but the field has advanced dramatically over the past decade with highly engineered containers and cooling technologies. Now, specialized containers for specific parts of the distribution channels of life sciences products are appearing. The latest involve the critical "last mile" delivery to the patient's home, and economical and dependable shipping of blood products. In the latter case, Sonoco ThermoSafe (Arlington Heights, IL) has announced the Via reusable
  •  
    What do 9.4 million lunches, breakfasts and funded coffee breaks do for the healthcare professions?
    Right on schedule, and with, according to CMS, 98.8% validated records (of a total of 11.41 million records), the Open Payments system delivered the results on calendar year 2014. Open Payments comes out of the Physicians Sunshine Act, requiring drug and medical device manufacturers to document "transfers of value" to physicians and teaching hospitals. Pharma and med-device spent a total of $6.49 billion on over 600,000 physicians and 1,100 teaching hospitals in that year, says CMS. In 2014, following several delays, CMS reported on the latter five months of 2013 under the Open Payments system, and with a sizable percentage of exclusions due to validation
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the September/October 2015 Issue now - It's Free!
COLD CHAIN FOCUS
Pharmaceutical Commerce’s annual Cold Chain Sourcebook projects 44% growth over the 2013–2019 span
 
INDUSTRY EVENTS
September 21-22, 2015
 
September 27-30, 2015
 
September 28-30, 2015
 
September 28-30, 2015
 
September 28-30, 2015
 
September 29-30, 2015
 
 
 
 
 
WHAT THEY'RE SAYING
Pharmaceutical Commerce sat down with Steve Collis, president and CEO of AmerisourceBergen since 2011, to see how the WBA partnership is going, and what lies ahead for the company. Here’s what he had to say.
 
 
FEATURES
Contract development and manufacturing organizations (CDMOs) want to be more reliable business partners to pharma  continued >
 
More volumes of more valuable products drive growth  continued >
 
Data-driven applications provide corresponding value based on the role and goal of the user  continued >
 
While the biopharma industry continues to develop better treatment options, there is a stronger focus on more intensive patient engagement  continued >
 
New IT tools are propelling a more focused approach to product launch  continued >
 
 
MOST POPULAR STORIES
 
 
SPECIAL FOCUS REPORT
The 2015 Biopharma Cold Chain Landscape
 
More volumes of more valuable products drive growth
 
CLINICAL OPERATIONS
Looking for a 'paradigm shift' in patient recruitment and retention on an international level 
 
 
 
   
  |     |     |     |     |     |  
©2015 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.